Emerging treatments
Roxadustat
Roxadustat (an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor) stimulates erythropoiesis and regulates iron metabolism. In a phase 3 trial of patients with chronic kidney disease not undergoing dialysis, treatment with roxadustat resulted in a higher mean haemoglobin level compared with placebo.[176] Roxadustat demonstrated continued efficacy in the open-label phase of the trial.[176] In a study of patients with anaemia undergoing dialysis, roxadustat demonstrated non-inferiority to epoetin alfa.[177]
Use of this content is subject to our disclaimer